Category Research

Gepotidacin’s positive phase III data shows potential to be the first in a new class of oral antibiotics for uncomplicated urinary tract infections in over 20 years

Gepotidacin’s positive phase III data shows potential to be the first in a new class of oral antibiotics for uncomplicated urinary tract infections in over 20 years GSK plc (LSE/NYSE: GSK) presented positive results from the pivotal EAGLE-2 and EAGLE-3…

Read MoreGepotidacin’s positive phase III data shows potential to be the first in a new class of oral antibiotics for uncomplicated urinary tract infections in over 20 years

mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA® (pembrolizumab), Receives PRIME Scheme Designation from the European Medicines Agency for Adjuvant Treatment of Patients with High-Risk Stage III/IV Melanoma Following Complete Resection

mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA® (pembrolizumab), Receives PRIME Scheme Designation from the European Medicines Agency for Adjuvant Treatment of Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering…

Read MoremRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA® (pembrolizumab), Receives PRIME Scheme Designation from the European Medicines Agency for Adjuvant Treatment of Patients with High-Risk Stage III/IV Melanoma Following Complete Resection

Imfinzi-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial

Imfinzi-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial Positive results from the AEGEAN Phase III trial showed that…

Read MoreImfinzi-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial